Implementation Process Article 5(3) Nitrosamine
Q&A for the implementation of the Article 5(3) referral. As a result of the call for review to MAHs for authorised medicines or for new MAAs, the MAH/applicant should forthwith inform CAs if N-nitrosamines are identified, irrespective of the amount detected.
Download Implementation Process Article 5(3) Nitrosamine
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Therapy Codes Update - Centers for Medicare & Medicaid ...
www.cms.govMay 26, 2020 · Implementation Date: MACs June 16, 2020 FISS - July 6, 2020 . Note: We revised this article to reflect a revised CR11791. The CR revisi on changed the implementation date for the MACs and we revised that date in the article. Also, we revised the CR release date, transmittal number, and the web address of the CR. All other information is the same.
onsultation Paper
www.eba.europa.euDraft Guidelines On policies and procedures in relation to compliance management and the role and responsibilities of the AML/CFT Compliance Officer under Article 8 and Chapter VI of Directive (EU) 2015/849 . ... for the implementation of the law, regulations and administrative provisions necessary to ...
onsultation Paper
www.eba.europa.euImplementation 17 4. Guidelines on the management of interest rate risk and on the assessment and monitoring of credit spread risk, arising from non-trading book activities 18 4.1 General provisions 18 4.2 Identification and management of IRRBB 20
Questions and answers to Stakeholders on the ...
www.ema.europa.euQuestions and answers to Stakeholders on the implementation of the Protocol on Ireland/Northern Ireland EMA/520875/2020 Page 2/11 information on medicinal products authorised in Northern Ireland recorded in Article 57 Database). The below guidance addresses the changes in article 57 database that will affect marketing authorisation holders. 2.1.